Lauren Bor - TC BioPharm Head Division
| TCBP Stock | USD 0.60 0.04 6.25% |
Executive
Lauren Bor is Head Division of TC BioPharm Holdings
| Address | Maxim 1, Motherwell, United Kingdom, ML1 4WR |
| Phone | 44 14 1433 7557 |
| Web | https://tcbiopharm.com |
TC BioPharm Management Efficiency
The company has return on total asset (ROA) of (1.0892) % which means that it has lost $1.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.1748) %, meaning that it created substantial loss on money invested by shareholders. TC BioPharm's management efficiency ratios could be used to measure how well TC BioPharm manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/30/2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -3.58. At this time, TC BioPharm's Total Current Liabilities is relatively stable compared to the past year. As of 11/30/2024, Liabilities And Stockholders Equity is likely to grow to about 10 M, while Non Current Liabilities Total is likely to drop slightly above 1.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alexander Epshinsky | Allarity Therapeutics | 41 | |
| Verender Badial | Zura Bio Limited | 52 | |
| Jose MD | Allarity Therapeutics | 67 | |
| Fiona Sharp | Biodexa Pharmaceticals | N/A | |
| Lily Fu | Virax Biolabs Group | N/A | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| Tim Varacek | LMF Acquisition Opportunities | N/A | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Gerhard Bauer | Immix Biopharma | N/A | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Dmitry MD | Biodexa Pharmaceticals | 44 | |
| Sai Iyer | LMF Acquisition Opportunities | N/A | |
| Joerg Heyer | Palisade Bio | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| David Brady | Zura Bio Limited | N/A | |
| Douglas MBA | Unicycive Therapeutics | 62 | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Ryker Willie | Palisade Bio | N/A | |
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 70 | |
Management Performance
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 |
TC BioPharm Holdings Leadership Team
Elected by the shareholders, the TC BioPharm's board of directors comprises two types of representatives: TC BioPharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TCBP. The board's role is to monitor TC BioPharm's management team and ensure that shareholders' interests are well served. TC BioPharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TC BioPharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MBA, CoFounder Chairman | ||
| Lauren Bor, Head Division | ||
| Martin Thorp, CFO Director | ||
| Christopher Camarra, Executive Communications | ||
| Bryan Kobel, CEO Director | ||
| Angela Scott, CoFounder COO |
TCBP Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is TC BioPharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 | ||||
| Current Valuation | 1.14 M | ||||
| Shares Outstanding | 572.02 K | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 38.33 K | ||||
| Price To Book | 0.13 X | ||||
| Price To Sales | 0.51 X | ||||
| Gross Profit | 3.84 M | ||||
| EBITDA | (13.61 M) |
Pair Trading with TC BioPharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.Moving together with TCBP Stock
Moving against TCBP Stock
| 0.83 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.81 | GILD | Gilead Sciences | PairCorr |
| 0.78 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.71 | VTRS | Viatris | PairCorr |
| 0.69 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.